Summary
Merck & Co., Inc. (MRK) reported solid third-quarter 2023 financial results, with total sales increasing by 7% year-over-year to $16.0 billion. This growth was primarily driven by strong performance in the oncology franchise, led by Keytruda, and robust sales from the vaccines franchise, particularly Gardasil 9. The company also saw positive contributions from the hospital acute care and cardiovascular segments. Despite overall sales growth, the company experienced a decline in the diabetes franchise due to increased competition and the impact of the Inflation Reduction Act on key products like Januvia. Operationally, the company recorded significant charges related to its strategic acquisitions of Prometheus Biosciences, Inc. ($10.2 billion) and Imago BioSciences, Inc. ($1.2 billion) in Research and Development expenses for the nine months ended September 29, 2023. This led to a substantial increase in R&D expenses for the period. The company also announced a significant global development and commercialization agreement with Daiichi Sankyo for three ADC candidates, which will result in a $5.5 billion pretax charge to R&D expenses in the fourth quarter of 2023. Despite these investments and charges, Merck maintained a strong cash flow from operations.
Financial Highlights
56 data points| Revenue | $15.96B |
| Cost of Revenue | $4.26B |
| Gross Profit | $11.70B |
| R&D Expenses | $3.31B |
| SG&A Expenses | $2.52B |
| Interest Expense | $317.00M |
| Net Income | $4.75B |
| EPS (Basic) | $1.87 |
| EPS (Diluted) | $1.86 |
| Shares Outstanding (Basic) | 2.54B |
| Shares Outstanding (Diluted) | 2.55B |
Key Highlights
- 1Total sales for the third quarter of 2023 increased by 7% to $16.0 billion, driven by oncology (Keytruda) and vaccines (Gardasil 9).
- 2Acquisitions of Prometheus Biosciences ($11.0 billion) and Imago BioSciences ($1.35 billion) significantly impacted R&D expenses in the nine-month period.
- 3A new global agreement with Daiichi Sankyo for three ADC candidates was announced, resulting in a $5.5 billion R&D charge in Q4 2023.
- 4Sales in the diabetes franchise (Januvia, Janumet) declined significantly due to loss of exclusivity and competitive pressures, with ongoing concerns regarding the Inflation Reduction Act.
- 5Cash flow from operating activities remained strong at $12.8 billion for the first nine months of 2023.
- 6The company is actively managing its capital structure, including issuing $6.0 billion in senior unsecured notes.
- 7The company continues to defend its intellectual property, with ongoing litigation related to key products like Januvia and Bridion.